In a Phase I trial (NCT01109095) using second-generation CD28.3ζ CAR T cells targeted against HER2/neu, an overexpressed TAA of GBM, no severe toxicities occurred for doses of up to 1 × 108 cells. The gene discussed is ERBB2; the disease is glioblastoma.